Marwa S Abdel-Tawab1, Hanan H Fouad2, Dalia A Omran3, Aml E Abdou4, Shaimaa Mohamed Zaied5, Alaa A Mohamed1,6. 1. Medical Biochemistry Department, Faculty of Medicine, Beni-Suef University, Egypt. 2. Medical Biochemistry Department, Faculty of Medicine, Cairo University, Egypt. 3. Endemic Medicine and Hepatology Department, Faculty of Medicine, Cairo University, Egypt. 4. Microbiology and Immunology Department, Faculty of Medicine, Al-Azhar University, Egypt. 5. Clinical and Chemical Pathology Department, Faculty of Medicine, Beni-Suef University, Egypt. 6. Medical Biochemistry Division, Pathology Department, Faculty of Medicine, Jouf University, Sakaka, Saudi Arabia.
Abstract
BACKGROUND: Hepatitis C virus (HCV) is considered a major global public health problem. Recently, there are great advances in HCV therapy, but there are some limitations that are creating an urgent need for assessment of some cytokines that have a potent antiviral effect in the immune system and anti-inflammatory effects to provide a potential novel immunotherapeutic target in HCV infection. OBJECTIVE: This study was directed to assess the serum levels and gene expression levels of Galectin-4 (LEG4), Interleukin-27 (IL-27), and Complement-7 (C-7) and their correlation with the viral load in HCV infection. Subjects and Methods. This work was conducted on 80 subjects, Group 1 (n = 40) early detected HCV patients and Group 2 (n = 40) healthy controls. LEG4, IL-27, and C-7 were assessed at the protein levels by ELISA, and their gene expression was assessed by RT-qPCR. The viral load was measured by PCR. RESULTS: There were significant elevations in the mean levels of gene expression and serum levels of all studied parameters LEG4, IL-27, and C-7 in the HCV group compared to the control group. Significant negative correlations between the viral load and each of the serum proteins and gene expressions of both LEG4 and IL-27 in HCV patients were found. The gene expression levels of LEG4, IL-27, and C-7 were positively correlated with their corresponding serum proteins in HCV patients. CONCLUSION: LEG4 and IL-27 showed significant negative correlations with the viral load, which could be an immune response to the control of the extent of hepatic inflammation, thus creating a potential novel immunotherapeutic approach in HCV infection for further studies or therapeutic clinical trials.
BACKGROUND: Hepatitis C virus (HCV) is considered a major global public health problem. Recently, there are great advances in HCV therapy, but there are some limitations that are creating an urgent need for assessment of some cytokines that have a potent antiviral effect in the immune system and anti-inflammatory effects to provide a potential novel immunotherapeutic target in HCV infection. OBJECTIVE: This study was directed to assess the serum levels and gene expression levels of Galectin-4 (LEG4), Interleukin-27 (IL-27), and Complement-7 (C-7) and their correlation with the viral load in HCV infection. Subjects and Methods. This work was conducted on 80 subjects, Group 1 (n = 40) early detected HCV patients and Group 2 (n = 40) healthy controls. LEG4, IL-27, and C-7 were assessed at the protein levels by ELISA, and their gene expression was assessed by RT-qPCR. The viral load was measured by PCR. RESULTS: There were significant elevations in the mean levels of gene expression and serum levels of all studied parameters LEG4, IL-27, and C-7 in the HCV group compared to the control group. Significant negative correlations between the viral load and each of the serum proteins and gene expressions of both LEG4 and IL-27 in HCV patients were found. The gene expression levels of LEG4, IL-27, and C-7 were positively correlated with their corresponding serum proteins in HCV patients. CONCLUSION: LEG4 and IL-27 showed significant negative correlations with the viral load, which could be an immune response to the control of the extent of hepatic inflammation, thus creating a potential novel immunotherapeutic approach in HCV infection for further studies or therapeutic clinical trials.
Authors: N Kondoh; T Wakatsuki; A Ryo; A Hada; T Aihara; S Horiuchi; N Goseki; O Matsubara; K Takenaka; M Shichita; K Tanaka; M Shuda; M Yamamoto Journal: Cancer Res Date: 1999-10-01 Impact factor: 12.701
Authors: Emily A Machala; Brian P McSharry; Barry T Rouse; Allison Abendroth; Barry Slobedman Journal: J Gen Virol Date: 2019-01-16 Impact factor: 3.891
Authors: Roniel Cabrera; Zhengkun Tu; Yiling Xu; Roberto J Firpi; Hugo R Rosen; Chen Liu; David R Nelson Journal: Hepatology Date: 2004-11 Impact factor: 17.425
Authors: Rebecca L Morgan; Brittney Baack; Bryce D Smith; Anthony Yartel; Marc Pitasi; Yngve Falck-Ytter Journal: Ann Intern Med Date: 2013-03-05 Impact factor: 25.391